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INVITED REVIEW
Biomaterials in the development and future of
vascular grafts
Lian Xue, MD, PhD,a and Howard P. Greisler, MD,a,b,c Maywood, Ill
Recent developments in the field of tissue engineering have re-invigorated the quest for more suitable biomaterials that
are applicable to novel cardiovascular devices, including small-diameter vascular grafts. This review covers both
commercially available and relevant newly developed experimental materials, including elastic polymers (polyurethane),
the biodegradable and bioresorbable materials, and the naturally occurring materials, focusing on their potential
applications in the development of future vascular substitutes. (J Vasc Surg 2003;37:472-80.)
The search for vascular substitute materials has thus far
been a half-century endeavor.1 The initial failure of materials
such as metal, glass, ivory, silk, and nylon brought 2 important
criteria into focus: thrombogenicity and durability. Research
was thus directed at inert materials that minimally interact
with blood and tissue. Polyethylene terephthalate (PET, Da-
cron) and expanded polytetrafluoroethylene (ePTFE) are the
products of this research and are currently the standard bio-
materials of prosthetic vascular grafts. Examined by means of
decades of use, both Dacron and ePTFE grafts have been
shown to perform well at diameters 6 mm, but neither
material has been suitable for small-diameter (4 mm)
applications. Thus, finding a solution for small-diameter
bypass grafting has become a major focus of attention. The
mid- to long-term failure of existing synthetic grafts is
essentially caused by unfavorable healing processes, namely
incomplete endothelialization and myointimal hyperplasia
(IH). Seeking completely non-reactive substances is likely
unrealistic. Optimizing tissue-biomaterial interactions to
elicit desirable results is thus a major emphasis of research.
Various modifications have been applied to Dacron and
ePTFE grafts to improve their function. Elastic polymers
have been used in the manufacture of compliant grafts on
the basis of the notion that compliance mismatch between
the synthetic graft and native artery may contribute to IH.
Biodegradable polymers can constitute a temporary scaf-
fold through which tissue ingrowth in vivo eventually re-
places the prostheses and leave a complete biological vas-
cular conduit. The emergence of tissue-engineering
technology has made the development of a novel biologi-
cally viable vascular substitute feasible, and it may prove to
be the ultimate solution for small-diameter vascular graft-
ing. The purpose of this review is to highlight currently
used and experimental biomaterials and their potential
applications in the development of future vascular grafts,
focusing on those used for conventional open vascular
reconstructions.
CURRENT MATERIALS
As aforementioned, the 2 standard polymers used for
vascular grafts in clinical practice are Dacron and ePTFE.
Both PET and PTFE molecules are highly crystalline and
hydrophobic, the 2 properties that prevent the polymers
from hydrolysis. The hydrophobicity of the polymer has
important implications in predicting surface interactions
with blood and tissue.
Dacron. PET was first introduced in 1939. DuPont
further developed it and patented its widely known Dacron
fiber in 1950.2 Vascular grafts made from Dacron were first
implanted by Julian in 1957 and DeBakey in 1958.1
Clinically available Dacron grafts are fabricated in ei-
ther woven or knitted forms. The multifilament Dacron
threads in woven grafts are fabricated in an over-and-under
pattern, which results in very limited porosity and minimal
creep of the finished graft. Knitted grafts are made with a
textile technique in which the Dacron threads are looped to
create greater porosity and radial distensibility. The velour
technique that extends the loops of yarn on the surfaces of
the fabrics has been used in an attempt to increase tissue
incorporation. A crimping technique is used to increase the
flexibility, distensibility, and kink-resistence of textile
grafts. Prosthetic rings or coils are applied to the external
surface of the grafts as external support to resist kinking and
possible mechanical compression.
The high porosity of the knitted graft necessitates pre-
clotting as a means of preventing transmural blood extrav-
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asation. Gelatin (Vascutek, Renfrewshire, Scotland), colla-
gen (Boston Scientific, Oakland, NJ), and albumin (Bard
Cardiovascular, Billerica, Mass) are used to seal knitted
Dacron graft pores. The gelatin and collagen in the Vas-
cutek and Boston Scientific grafts are cross-linked by low
concentrations of formaldehyde, a method that results in a
weak linkage that allows the gelatin or collagen to be
degraded in the body in 2 weeks.3,4 Bard uses glutaral-
dehyde to cross-link albumin, and the albumin is absorbed
in 2 months.5
Dacron has a good stability and can persist for more
than 10 years after implantation without significant deteri-
oration. However, knitted Dacron grafts have been prone
to dilate when implanted into the arterial environment,
more because of fabrication technique than the polymer
itself.6,7 Direct etiological association between graft dila-
tion and the later clinical complications has been rare.8
Other than this, there are no clinical differences grafts in
complications and graft patency between woven and knit-
ted grafts in their use as aortoiliac bypass grafts.9 Five-year
patency rates are 93% for aortic bifurcation grafts,10 but
only 43% for above-knee femoropopliteal bypass grafts,11
and even lower for below-knee grafts.
Blood and tissue reactions to implanted grafts start
immediately after the restoration of circulation. The first
step is a dynamic protein adsorption/desorption to syn-
thetic material surfaces, known as the Vroman effect,12
followed by platelet adhesion, inflammatory cell infiltra-
tion, and endothelial cell (EC) and smooth muscle cell
(SMC) migration.13,14 A coagulum containing fibrin,
platelets, and blood cells builds up during the first few
hours to days and stabilizes in a period of 6 to 18 months,
forming a compacted layer.15 The histological characteris-
tics observed within Dacron grafts is a compact fibrin layer
on the blood-contacting surface and densely packed for-
eign body giant cells between the outer layer of the graft
wall and surrounding connective tissue capsule. The fibrin
layer within the midgraft remains acellular, regardless of
whether the grafts are woven or knitted. An external velour
surface permits more extensive and firmer incorporation of
the graft into surrounding tissue, but the function of an
internal velour structure remains controversial, with the
suggestion that it may enhance firm anchorage of the
fibrin/platelet pseudointima.14,15 Protein impregnation
changes the surface properties of Dacron grafts and may
induce more inflammatory reaction, but it does not change
the clinical patency rates of these grafts.3,16,17
A heparin-bonded Dacron graft by InterVascular (La
Ciotat, France) is currently available on the European
market. The heparin is bound primarily through Van der
Waals bonds to the polyester fiber that is pretreated with a
cationic agent, tridodecil-methyl-ammonium chloride
(TMAC). The external third of the graft wall is coated with
collagen to prevent blood extravasation.18 In a comparative
clinical trial involving 209 patients undergoing femoropop-
liteal bypass grafting, the heparin-bonded Dacron graft
exhibited slightly better patency rates at 1, 2, and 3 years of
70%, 63%, and 55%, respectively, compared with rates of a
untreated ePTFE graft of 56%, 46%, and 42%, respective-
ly.19 The significance of heparin bound to synthetic grafts
will be further discussed in this review.
Expanded polytetrafluoroethylene. PTFE was pat-
ented by DuPont in 1937 as Teflon. Because of its partic-
ular relatively inert characteristics, it was considered to be
an ideal electrical insulator.2 Its medical use began with its
application in artificial heart valves in the early 1960s. In
1969, Gore patented expanded ePTFE (Gore-tex), which
is the material used in vascular grafts. The expanded poly-
mer is manufactured by means of a heating, stretching, and
extruding process that produces a microporous material
more supportive of firm tissue adhesion.
The PTFE molecule is biostable, and the graft made
from it does not undergo biological deterioration within
the body. The surface of the graft is electronegative, which
minimizes its reaction with blood components. ePTFE
grafts are manufactured by means of stretching a melt-
extruded solid polymer tube, which then cracks into a
non-woven porous tube. The characteristic structure of
ePTFE is a node-fibril structure in which solid nodes con-
nect through fine fibrils, with an average internodal dis-
tance of 30 m for a standard graft.
Like Dacron grafts, ePTFE grafts perform well as aortic
substitutes, with a 5-year primary patency rate of 91% to
95%.10,17 When used for femoropopliteal bypass grafting,
the 3- and 5-year patency rates are only 61%20 and 45%,11
respectively, whereas the autogenous vein grafts have 5-
and 10-year cumulative patency rates of 77%21 and 50%,
respectively.22
The initial host response to ePTFE grafts is similar to
that of Dacron grafts.13-15 A fibrin coagulum or amor-
phous platelet-rich material develops in a time sequence
that is similar in both materials. Lack of luminal surface
cellular coverage can be found at the midgraft region years
after human implants.23-25 In the outer wrap-reinforced
graft, the wrap limits the infiltration of the cells from
perigraft tissue and leaves acellular fibrin matrix inside the
graft wall.15 The densely fabricated wrap is manufactured
on the outer surface of some of the Gore-tex grafts as a
reinforcement to the graft wall. This wrap was beneficial in
reducing post-implantation dilation. However, with the
newer manufacturing technologies currently used, the wrap
is felt by many investigators to be unnecessary.
Several modifications to the basic graft have been pro-
posed for improving its function. One is to increase the
graft permeability on the basis of the notion that the rate of
tissue ingrowth is associated with graft porosity (in limited
porosity ranges) and that transmural capillary ingrowth can
provide the cell source for the surface endothelialization. In
a baboon model, enhanced tissue ingrowth with complete
endothelialization occurred in ePTFE grafts with a 60-m
or 90-m internodal distance, but the 90-m internodal
graft demonstrated focal areas of neointimal desquamation
at late periods.26 Increased tissue ingrowth and EC cover-
age and higher patency rates of the high-porosity ePTFE
have also been reported in canine models.27,28 However, a
human trial with high-porosity ePTFE failed to show any
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advantage in platelet deposition as compared with standard
30-m internodal distance ePTFE grafts.29
Another modification has focused on the luminal sur-
face of the graft. Carbon coating is used to increase the
surface electronegativity so as to diminish thrombus forma-
tion. Early studies demonstrated decreased platelet deposi-
tion on carbon-coated grafts, but the overall patency rates
were not improved when compared with those of uncoated
grafts.28,30 A prospective multicenter clinical study, con-
sisting of 81 carbon-impregnated ePTFE and 79 standard
ePTFE grafts for below-knee popliteal and distal bypass
grafting, showed no difference in patency rates between the
2 groups as long as 2 years after implantation.31 However,
a recent report on a multicenter trial in Europe involving
128 carbon-coated ePTFE and 126 standard ePTFE grafts
for infrainguinal bypass grafting demonstrated the signifi-
cantly greater 1- and 2-year patency rates of the carbon-
coated versus the standard grafts by means of life-table
analysis.32
The attachment of anticoagulant or antithrombotic
agents to the graft has also been explored. The most
investigated is heparin binding. Heparin-bound ePTFE
grafts demonstrated reduced thrombogenicity and im-
proved patency rates at 8 weeks compared with the stan-
dard graft in the rat infrarenal aortic position.33 Whether
the anticoagulation works through continuous release of
heparin from the material that establishes an effective con-
centration at the interface between blood and the graft
surface or through non-consumptive mechanisms of active
function of the heparin immobilized on the material surface
is unclear. A major concern with the administration of
heparin on the graft surface is the duration of heparin
function. Premature release or disturbance of functional
heparin or the presence of a physical barrier because of
adherent blood components implies a theoretical inefficacy
of the approach. In a recent report by Fisher et al from Gore
& Associates,34 heparin was covalently linked to a pre-
treated bioactive surface of ePTFE grafts, which were then
implanted into canine aortoiliac arteries. The surface hep-
arin activity measured by means of antithrombin III uptake
per unit area was 24.7  7.9 pmol/cm2 at 2 weeks and
remained at 15.3  3.7 pmol/cm2 at 12 weeks. Although
it seems promising, the actual benefit of this treatment
needs to be proved in longer-term in vivo studies.
Various bioactive substances have been integrated onto
synthetic grafts by means of a number of delivery methods
to modulate the graft healing process. One example is fibrin
glue (FG) delivery of growth factors onto the ePTFE grafts.
The growth factors can be slowly released from the FG,
retaining their bioactivities in vivo. ePTFE grafts impreg-
nated with FG containing fibroblast growth factor (FGF)-1
and heparin that were implanted into canine bypass graft
models elicited greater endothelialization and tissue incor-
poration than untreated or FG/heparin (no FGF) treated
grafts.35,36 Many growth factors, such as FGF-2, platelet-
derived growth factor, and vascular endothelial growth
factor, have been tested by using various delivery systems.14
Although most of the earlier studies were done on synthetic
grafts, the concept may also apply to scaffolds, which will be
discussed.
More experimental modifications have been reviewed
elsewhere.14
Despite the difference in both chemical and physical
properties between ePTFE and Dacron grafts, the patency
rates are comparable at all positions.10,11,37,38 Little or only
marginal clinical improvement has been achieved from
various modifications of the basic grafts.
Elastic polymer—polyurethane. Both ePTFE and
Dacron grafts are relatively non-compliant. The compli-
ance mismatch has been thought to contribute to the
development of IH at the anastomotic regions.39 Elastic
polymers have been introduced to create radially compliant
vascular grafts.
Polyurethanes (PUs) were originally developed com-
mercially in Germany in the 1930s as surface coatings,
foams, and adhesives.40 Segmented PUs are copolymers
comprising 3 different monomers, a hard domain derived
from a diisocyanate, a chain extender, and a soft domain,
most commonly polyol. The soft domain is mainly respon-
sible for flexibility, whereas the hard domain imparts
strength. The selection of the 3 monomers can produce
materials with different mechanical characteristics, which
makes PU an attractive biomaterial. Lycra is the trade name
of a segmented polyether PU that was commercialized in
1962 by DuPont.
As a biomaterial, PU was first used in manufacturing
implantable roller pumps and left ventricular assist devices
and as a coating for early artificial hearts.41 The superior
elastic and compliant mechanical properties and acceptable
biocompatibility of PU make it an appealing material for
vascular grafts. Developing PU-based small-diameter vas-
cular grafts has attracted great interest from industry.
The first generation of PU vascular grafts was devel-
oped with polyester PUs, which resulted in devices such as
Vascugraft by B. Braun Melsungen AG (Melsungen, Ger-
many). Although the initial report demonstrated good
biocompatibility,42 the graft underwent surface chemical
modification and deterioration in vivo.43,44 A clinical trial
with Vascugraft for below-knee bypass grafting was aborted
after 8 of 15 grafts had occluded in the first year.44 It has
been reported that PUs with polyester polyols as soft seg-
ments are hydrolytically unstable.45
Polyether-based PUs, such as in the Pulse-Tec (Newtec
Vascular Products of North Wales, UK) vascular access
graft, were then used. Polyetherurethane was relatively
insensitive to hydrolysis but susceptible to oxidative degra-
dation.45 The Pulse-Tec graft suffered from in vivo biodeg-
radation and died in the product pipeline. Vectra (Thoratec
Laboratories Corporation, Pleasanton, Calif) is another
vascular access graft made with polyetherurethaneurea. The
graft is manufactured with an average pore size of 15 m
and a non-porous layer under the luminal surface, which
makes it impervious to liquids.46 In a multicenter trial
involving 142 patients receiving either Vectra or ePTFE
vascular access grafts with a follow-up time as long as 12
months, no difference was found in the patency or compli-
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cation rates of the 2 grafts, but the Vectra grafts allowed
earlier access.47 However, it was noted that the PU graft
elongated with time after implantation, and the incidence
of pseudointimal formation near the anastomosis was
higher than that in the ePTFE grafts. The Vectra graft
received Food and Drug Administration (FDA) clearance
in 2000. A small-diameter coronary bypass graft created by
the company with the same material is currently undergo-
ing clinical trial.
A new generation of PU grafts uses polycarbonate-
based PUs that eliminate most ether linkages and thus are
hydrolytically and oxidatively stable and more resistant to
biodegradation.48 A non-woven poly(carbonate)urethane
graft, fabricated with a spray phase-inversion technique,
showed no significant degradation for as long as 6 months
in rat aorta.49 The graft demonstrated faster endotheliali-
zation, early stabilization of neointimal proliferation, and a
thinner neointima compared with ePTFE grafts. The Cor-
vita graft (Corvita, Miami, Fla), comprising a porous poly-
carbonate PU inner tube filled with a glutaraldehyde cross-
linked gelatin-heparin matrix reinforced on the outside
with knitted Dacron mesh, displayed no signs of aneurysm
at 1 year after implantation in canine femoral arteries.50
When compared with ePTFE grafts, the PU graft overall
showed no appreciable difference in neointimal formation
in the canine aortic model.51 The graft made of poly(car-
bonate-urea)urethane (Chronoflex, CardioTech Interna-
tional, Woburn, Mass) is expected to have better stability
because the polymer has no ether/ester linkages. The good
stability of the graft was indicated both in vitro and in
vivo.52-54 In a small animal study, the grafts were implanted
in aortoiliac arteries in 4 dogs for 36 months.55 No evi-
dence of polymer degradation or graft deterioration was
found. Histologically, there was IH in midgraft regions and
around anastomoses, cellular infiltration and collagen dep-
osition inside the wall, and a fibrous capsule on the outer
surface of the graft with, reportedly, no foreign body reac-
tion. The graft is currently undergoing clinical trial. Car-
boxylated PU treatment of the graft can create a surface
with reactive carboxylic acid groups to which hirudin has
been covalently bound.56 The antithrombin activity of
immobilized hirudin may be expected to improve the graft
performance.
Tissue reactions to PU grafts are discrepant in the
literature because factors such as different compositions of
polymers, graft fabrication, porosity, and surface modifica-
tions all affect the results.56-58 No conclusion can be made
at this point as to whether PU grafts may be functionally
superior to ePTFE or Dacron grafts until more data be-
come available.
There have also been attempts at using PU with other
biodegradable materials in the manufacture of biodegrad-
able vascular grafts, which will be discussed. One major
concern about PU grafts is the potential carcinogenic effect
of its degradation products. In 1991, the FDA terminated
the use of PU foam as a surface-coating material for breast
implants, after it had been marketed for 20 years. A
statement issued by the FDA suggested that the implanted
foam might degrade and form 2,4-toluene diamine, which
has been shown to cause liver cancer in laboratory animals.2
The extent to which the initial compliance may affect
the long-term function of the graft remains controversial.59
It has long been realized that fibrous tissue formation
within and surrounding an implanted graft would compro-
mise graft compliance. In a follow-up study of 8 patients
with iliofemoral artery woven Dacron grafts, the average
graft diameter variation during the cardiac cycle was 6% at 1
month after implantation, and it decreased to 1% after 1
year.60 The mechanical behavior of vascular grafts in vivo is
governed not only by the properties of the implanted graft,
but also by the nature and the amount of tissue incorpora-
tion.
PRE-CLINICAL INVESTIGATIONAL
BIOMATERIALS FOR VASCULAR GRAFTS AND
TISSUE-ENGINEERING SCAFFOLDS
Biodegradable and bioresorbable polymers
Tissue-biomaterial interactions, which ultimately often
result in graft failure, are inevitable as long as the prosthesis
remains implanted. Bioresorbable polymers possess the ad-
vantage of leaving behind no prosthetic materials to keep
stimulating persistent foreign-body reactions. Biodegrad-
able polymers, however, undergo fragmentation with ex-
posure to biological environments, which results in smaller
degradation products that may or may not remain present
either at the implantation site or in distant locations, such as
the lymphatic system.61 Theoretically, it is possible to tis-
sue-engineer a “neoartery,” assuming there is adequate
load bearing to resist dilation and include cellular compo-
nents with desirable physiologic characteristics.
The 2 most investigated bioresorbable polymers are
polyglycolic acid (PGA) and polylactic acid (PLA). PGA is
highly crystalline and is hydrophilic. It was used to make the
first synthetic absorbable suture. The suture loses its me-
chanical strength 2 to 4 weeks after implantation because of
in vivo hydrolytic degradation of the polymer.62
PLA is more hydrophobic than PGA because of the
presence of an extra methyl group in the lactide molecule,
which limits the water uptake and results in a lower hydro-
lysis rate. Lactic acid is a chiral molecule that, therefore,
exists in 2 stereoisomeric forms, D-PLA and L-PLA. L-
PLA is semicrystalline with high mechanical strength, and
its hydrolytic product is naturally occurring L-lactic acid.
Thus it is more frequently used in scaffold design.
The copolymers of glycolic acid and lactic acid mar-
keted under the trade name Vicryl and polyglactin 910
(PG910) are widely used in the medical field as absorbable
sutures, orthopedic devices, and drug-delivery systems.62
Biodegradation, tissue regeneration, and mechani-
cal strength. A fully bioresorbable vascular graft made
from Vicryl sheets was investigated in 1979.57 These early
grafts were prone to aneurysmal dilation and rupture.
Grafts composed of woven PGA have been evaluated in a
rabbit model in our laboratory.63,64 An inner capsule com-
posed of a confluent layer of ECs and smooth muscle-like
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myofibroblasts amid dense collagen fibers was formed 4
weeks after implantation. Macrophage infiltration and
phagocytosis were in parallel with the resorption of the
PGA, which no longer could be identified within 3 months.
In this initial experiment, 10% of the PGA grafts showed
aneurysmal dilation, with no difference between 1 to 3
months and 3 to 12 months, which suggests that the critical
time for the development of aneurysms is during prosthetic
resorption, before the ingrowth of tissue with adequate
strength to resist hemodynamic pressures.
Polydioxanone (PDS), a material used clinically in bone
pins and suture clips, is a more slowly resorbed compound.
Grafts made of PDS showed similar endothelialization of
the regenerated luminal surface after implantation, and
PDS remained present for as long as 6 months. The ex-
planted specimens of these PDS grafts were able to with-
stand mean static bursting pressures of 6000 mm Hg and
2000 mm Hg without fatigue.65
A critical feature of bioresorbable grafts is that they
must regenerate a tissue complex of sufficient strength
before loss of prosthetic integrity to minimize the possibil-
ity of aneurysmal dilation as a requirement for clinical
efficacy.
Grafts constructed from 2 bioresorbable polymers
with different resorption rates or from bioresorbable poly-
mers with a non-resorbable material component have been
designed to dictate mechanical strength considerations.
The woven grafts composed of yarns of 74% PG910 and
26% PDS demonstrated a 100% 1-year patency rate, with
no aneurysms in the rabbit aorta model.66 The PG910 was
totally resorbed within 2 months, and the PDS was totally
resorbed within 6 months. The regenerated arteries with-
stood 800 mm Hg of pulsatile systolic pressure ex vivo
without bursting. Partially resorbable grafts containing
69% PG910 and 31% polypropylene or 70% PDS and 30%
polypropylene were implanted into canine aortoiliac arter-
ies. The overall patency rate was 90% for PG910/polypro-
pylene and 86% for PDS/polypropylene for as long as 1
year, with no aneurysms.67 PG910 was totally resorbed
within 2 months, and PDS was totally resorbed within 4
months. Both grafts elicited tissue ingrowth, which re-
mained histologically stable from 4 months through 1 year.
Polypropylene was chosen as the non-resorbable compo-
nent because Dacron was found to inhibit the arterial
regeneration stimulated by the resorbable component.67
Grafts prepared from a mixture of 5% PLA and 95% PU
were evaluated in rat aorta.68,69 The grafts formed neointi-
mas in 6 weeks and neomedias with elastic laminae in 12
weeks after implantation, but aneurysmal dilatation devel-
oped in 3 of 8 grafts, and another 2 dilated after 1 year.
PU/PLA lattices started to disintegrate on day 12 and
completely fragmented within 1 year. The authors sug-
gested that a relatively compliant scaffold was necessary to
induce circumferential orientation of SMCs. As aforemen-
tioned, the initial graft compliance can be compromised by
tissue ingrowth in vivo. A graft comprised of a poly-
etherurethane scaffold and sealed with polyethylene glycol
(PEG)/PLA copolymer exhibited good compliance, and
the compliance increased with the degradation of the
PEG/PLA components in vitro. Yet, when implanted in
vivo, the compliance reduced 20% after 12 weeks.70
Scaffolds for in vitro tissue engineering. After initial
attempts at directly implanting bioresorbable grafts that are
totally dependent on tissue ingrowth in vivo, cell seeding
onto bioresorbable scaffolds has been exploited to initiate
functional tissue regeneration. SMC seeding onto PU/
PLA scaffolds was found to enhance neomedia generation
and optimal media cell orientation.58 A Harvard-Massa-
chusetts Institute of Technology group led by Langer and
Vacanti constructed a tubular scaffold with woven polygla-
ctin as an outer layer and non-woven PGA as an inner
layer.71 Autologous cells with mixed population from arte-
rial explants were seeded onto the scaffolds. After 7 days of
in vitro culture, the constructed vessels were implanted into
ovine pulmonary arteries. All 7 were patent for as long as 12
weeks. The polymer scaffold was replaced by cells and
extracellular matrix (ECM) with time. However, the vessels
demonstrated an increase in diameter. They then designed
a more durable PGA/polyhydroxyalkanoate (PHA) scaf-
fold.72 The inner layer was made of non-woven PGA
designed to degrade in 6 to 8 weeks, and the outer layer was
made of nonporous PHA. PHAs are naturally occurring
polyesters produced by several microorganisms.62 They can
be degraded by hydrolysis, but have a degradation time of
years. The PHA homopolymers are highly crystalline, rela-
tively hydrophobic, and usually extremely brittle. Copoly-
mers such as hydroxybutyrate with hydroxyvaleric acid are
less crystalline and more flexible. The PHA used in this
study was a copolymer of polyhydroxyoctanoate (PHO)
and hydroxyhexanoic acid and has a high tensile set of 35%
after 100% elongation. The constructed scaffolds had good
tensile strength, flexibility, and handling. Using this scaf-
fold, the authors showed that all the tissue-engineered
vessels were patent, with no aneurysms for as long as 150
days after implantation into ovine abdominal aorta. The
PGA layers were completely replaced by tissue within 3 to 4
months. Development of endothelium and of a media,
containing collagen with the presence of elastin fibers, was
evident.72
Organized tissue can only be generated in appropriate
mechanical conditions. Culturing SMC-seeded PGA scaf-
folds with pulsatile flow for 8 weeks results in organization
of SMCs into multilayer structures with orientated collagen
fibrils between cells. The vessel structure displayed a con-
tractile response to vasoconstrictors, although the magni-
tude was only 15% to 20% of that of the native artery.73 The
ECM accumulates after exposure to in vivo hemodynamic
environments. The content of elastin and proteoglycans
was demonstrated by means of biochemical analysis to peak
at 8 and 16 weeks after implantation, respectively, after
exceeding their native artery levels and then decreased,
approaching that of native artery. Nevertheless, collagen
content continuously increased to approximately 5 times
that of the native artery within 24 weeks, without decline.74
ECM deposition is necessary for the establishment of graft
strength, but excessive matrix formation indicates unfavor-
JOURNAL OF VASCULAR SURGERY
February 2003476 Xue and Greisler
able tissue remodeling. Much still needs to be learned to
control this balance.
The PGA polymer does not possess cell-anchoring
sites. Surface modifications have been investigated to facil-
itate cell attachment, spatial cell distribution, or both.
Treatment with 1N NaOH transforms ester groups on the
surface of PGA fibers to carboxylic acid and hydroxyl
groups. The resultant hydrolyzed surface increased its ad-
sorption of serum proteins and doubled seeded SMC at-
tachment density.75 Incorporation of the RGD sequence to
the polymer surface can direct receptor-mediated cell ad-
hesion.76 Patel et al77 synthesized a biotinylated PLA-PEG
(polyethylene glycol) copolymer. Biotinylated-RGD pep-
tide was immobilized on the polymer surface by avidin.
With patterning technology, the authors were able to
achieve a controlled directed cell distribution. ECs adhered
and spread only on the RGD-functionalized lines, sepa-
rated by no cell zones in between. This technique and the
concept of controlling specific cell distribution represent
new possibilities in the tissue engineering field.
It has been noticed that SMCs in proximity to residual
PGA fragments display an undifferentiated phenotype that
is evidenced by a high mitotic rate and low expression on
contractile proteins.58 Degradation of polymer can pro-
duce acidic products and create a low pH microenviron-
ment, which stimulates chronic inflammation and induces
fibrocollagenous tissue formation that impairs the compli-
ance of the graft and eventually may cause graft failure.
Synthetic protein-based polymer. Synthetic protein-
based polymers, such as elastic protein-based polymer,
represent a new class of biomaterial. They are produced by
means of recombinant DNA technology and are biocom-
patible and biodegradable. A model polymer is poly
(GVGPV), the core sequence of which is a highly conserved
repeating sequence in elastin. Poly (GVGVP) cross-linked
with -irradiation exhibited an elastic modulus that was
similar to the femoral artery.78 Degradation of the polymer
can be achieved by the incorporation of carboxyamides
containing amino acids such as asparagine and glutamine
into the chain. The carboxyamides hydrolyze to form car-
boxylates, resulting in polymer breakdown. Depending on
the preceding and following amino acids, the degradation
can occur at times ranging from days to years. Conse-
quently, chemical clocks can be introduced to control the
polymer degradation rate. Cell attachment can be achieved
by means of incorporating RGD sequences into the poly-
mer. It has been shown that ECs among other cell types can
attach to polymer poly(40[GVGVP], [GRGDSP]), spread,
and grow to confluence.79 Both remarkable elasticity and
controllable degradation make elastin-based polymers po-
tentially desirable materials for scaffolds in blood vessel
tissue engineering.
Naturally occurring materials
The advantage of synthetic materials is that their mi-
crostructure, strength, and speed of degradation can be
controlled during production; natural materials, however,
facilitate cell repopulation and tissue remodeling.
Type I collagen. Type I collagen is a major compo-
nent of most connective tissues and is present throughout
the arterial wall. Its native state is resistant to most proteases
but is readily degraded by a wide variety of proteases once
denatured.80 Increasing intermolecular cross-links among
its 3 consisting peptide subunits can increase the tensile
strength of collagen fibers and make it less susceptible to
degradation. It has long been recognized that collagen,
with its integrin-binding domains, facilitates cell attach-
ment and that a collagen matrix can support tissue growth.
Because of its unique biological and physical properties,
collagen has been extensively used in tissue-engineering
applications.
The first complete tissue-engineered biological blood
conduit was constructed in 1986, with collagen gel as the
scaffold.81 Cultured bovine SMC and fibroblasts were sep-
arately embedded in collagen gel and assembled to form
media and adventitia. ECs were seeded to the luminal
surface to form a monolayer of endothelium. Although the
graft obtained 92% EC coverage on the inner surface and
longitudinal SMC organization, it failed to show the req-
uisite mechanical strength, even when reinforced with Da-
cron meshes. L’Heureux et al in 1993 modified this model
by using human umbilical vein ECs and SMCs and human
skin fibroblasts.82 They encountered the same mechanical
limitation. To improve the mechanical strength of the
collagen constructs, several approaches have been used.
Appropriate culture media and mechanical conditioning of
the constructed conduit stimulate its histological organiza-
tion and improve its mechanical strength.83-85 Fabricating
collagen/elastin fibers into scaffolds with techniques such
as electrospinning instead of by using a collagen hydrogel
represents a new approach that may eventually be able to
provide enhanced scaffold strength.86
Decellularized biological scaffolds. To obtain a
physiologic matrix scaffold resembling that of the native
artery, decellularized native vessel was introduced.87-90
The cells with their surface antigens are removed by means
of detergent and enzymatic extraction methods, leaving a
well-preserved acellular matrix that provides a scaffold for
autologous cell ingrowth and allows favorable tissue re-
modeling. Allogenic scaffolds have achieved minimal im-
munoreactivity and good durability for as long as 6 years,
without aneurysmal degradation.87 Initially, patency was
reported in 15 of 16 implants at 3 days to 6 years in canine
femoral and carotid arteries,87 but a later study showed 5 of
9 implants failed from acute occlusion in coronary bypass
grafts, and only limited cellular repopulation occurred in a
follow-up period of 6 months.88 Detergent was eliminated
from the process because of a concern that its remnant may
be cytotoxic. The difficulties with the supply of human
materials impose a significant limitation on allogeneic scaf-
folds. In this respect, xenogeneic materials have an advan-
tage. However, unlike allogeneic grafts in which the ECMs
bear little antigenicity, interspecies matrix immunogenicity
exists for xenografts.89 Xenogeneic acellular scaffolds elicit
significant chronic immunoresponsive inflammation,
which is sufficient to destroy elastin structures.90,91 It is
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necessary to either remove or mask the antigens from
structural proteins for xenogeneic sources to be used in
vascular tissue engineering.
Autologous EC seeding was expected to address both
the thrombogenicity of exposed collagen and the remain-
ing antigenicity of the matrix, but the actual results have
been disappointing.92,93 When decellularized allogeneic
porcine carotid matrix seeded with autologous ECs was
tested in carotid arteries, 46% of the 2-cm-long grafts failed
within 1 week. The remaining grafts had a patency rate of
71% at 4 months. The patent grafts had well-preserved
collagen and elastin structures, EC coverage, myofibroblast
ingrowth, and some degree of inflammatory reaction at
explantation.93
Scaffolds constructed from decellularized porcine in-
testine with cross-linked type I bovine collagen deposited
on the luminal surface have also been tested. The constructs
reportedly provided the necessary mechanical and hemody-
namic properties at implantation, and the scaffold was
cellularized and remodeled within 90 days in rabbit carotid
artery bypass graft models.94 Implanted as canine femoral
artery interposition grafts, the constructs demonstrated
myofibroblast repopulation through the scaffold and in-
complete endothelial coverage. Eight of 9 grafts were
patent for as long as 9 weeks, but with significant anasto-
motic IH. The diameter reductions were 7% at midgraft
and 56% and 42% at proximal and distal anastomoses,
respectively. No aneurysmal dilation was documented, but
non-infectious seromal cavities around the grafts developed
in all dogs at various points.95 No prediction can currently
be made on the prospect of this approach.
ENDOVASCULAR GRAFTS
Endovascular grafting to date has used variations of the
same class of biomaterials that are currently used for open
graft placement. However, a substantial effort is underway
to develop novel chemistries, biomechanics, and surface
modifications for these devices, work that is beyond the
scope of this review. The biomaterials discussed in this
review are mainly focused on conventional vascular grafts.
Most of the principles are applicable to endovascular grafts.
However, certain distinctive aspects should be considered
for endovascular graft development. For instance, endovas-
cular grafts require an extremely thin-wall design, which
enables them to be compressed to fit into a delivery sheath
or catheter. The porosity requirement for endovascular
grafts may not necessarily be the same as for conventional
grafts. The wall structure of the grafts may be affected by
deployment procedures. In addition, endovascular grafts
are surrounded by blood clots and atherosclerotic lesions,
which may result in tissue reactions that are different from
that of the conventional grafts.
CONCLUSIONS
ePTFE and Dacron are the standard materials for large-
diameter vascular grafts, but no ideal alternative to autolo-
gous vein grafts is currently available for small-diameter
applications. We are on the verge of integrating our under-
standing of biological reactions to vascular grafts with the
principles of tissue engineering and innovations of technol-
ogy to develop a new generation of vascular substitutes. A
living vascular graft with predictable and desirable biolog-
ical functions will likely be constructed by culturing blood
vessel cells on biological/synthetic scaffolds in bioreactors
with optimal hemodynamic and biomechanical conditions
and supplemented with spatially and temporally controlled
3-dimensional delivery of bioactive agents, the use of ge-
netic engineering techniques, or both. This may provide
the ultimate solution for the current dismal long-term
patency rates of small-caliber synthetic grafts.
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